Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Peters S, et al. Among authors: irigoyen a. Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31200833 Clinical Trial.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Irigoyen A, et al. Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28222309 Clinical Trial.
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Mesía R, et al. Among authors: irigoyen a. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. Epub 2015 Oct 22. Int J Radiat Oncol Biol Phys. 2016. PMID: 26675064 Clinical Trial.
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Hitt R, et al. Among authors: irigoyen a. Ann Oncol. 2012 Apr;23(4):1016-22. doi: 10.1093/annonc/mdr367. Epub 2011 Aug 23. Ann Oncol. 2012. PMID: 21865152 Free article. Clinical Trial.
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Hitt R, et al. Among authors: irigoyen a. Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19. Ann Oncol. 2014. PMID: 24256848 Free article. Clinical Trial.
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, Lambea J, Lecumberri MJ, Cruz JJ. Martinez-Trufero J, et al. Among authors: irigoyen a. Br J Cancer. 2010 Jun 8;102(12):1687-91. doi: 10.1038/sj.bjc.6605697. Epub 2010 May 18. Br J Cancer. 2010. PMID: 20485287 Free PMC article. Clinical Trial.
Consensus on the treatment of pancreatic cancer in Spain.
Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Hidalgo M, et al. Among authors: irigoyen a. Clin Transl Oncol. 2009 May;11(5):290-301. doi: 10.1007/s12094-009-0357-3. Clin Transl Oncol. 2009. PMID: 19451062 Review.
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, Safont MJ, Falcó E, Lacasta A, Reboredo M, Aparicio J, Dueñas R, Muñoz ML, Regueiro P, Sanchez-Viñes E, López RL. Gómez-Martin C, et al. Among authors: irigoyen a. Clin Transl Oncol. 2012 Sep;14(9):689-97. doi: 10.1007/s12094-012-0858-3. Epub 2012 Jul 19. Clin Transl Oncol. 2012. PMID: 22855151 Clinical Trial.
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E. Aranda E, et al. Among authors: irigoyen a. Ann Oncol. 2012 Jul;23(7):1919-25. doi: 10.1093/annonc/mdr560. Epub 2011 Dec 9. Ann Oncol. 2012. PMID: 22156621 Free article. Clinical Trial.
53 results